CHMP issues positive opinion for 20-Valent Pneumococcal Conjugate Vaccine for the prevention of vaccine-type pneumococcal pneumonia in adults- Pfizer.
The CHMP’s positive opinion will now be reviewed for this indication by the European Commission (EC). The decision on whether to approve PCV20, whose European Union (EU) trade name will be Apexxnar, will be made by the EC and will be applicable to all 27 EU member states plus Iceland, Lichtenstein and Norway.
Related news and insights
Sorrento Therapeutics, Inc. announced receipt of clearance from the Brazilian regulatory agency (ANVISA) to proceed with a Phase IIA randomised, placebo-controlled study of intravenous allogenic adipose-derived mesenchymal stromal cells to treat Post COVID 19 "Long Haul" Pulmonary compromise (NCT04992247).
Amryt presents long-term safety and efficacy data from the open-label extension (OLE) of its global Phase III MPOWERED non-inferiority clinical trial that compared Mycapssa (oral octreotide capsules) to long-acting iSRLs (injectable Somatostatin Receptor Ligands) for maintenance of biochemical response in patients with acromegaly.
Positive results from the TOPAZ-1 Phase III trial showed AstraZeneca’s Imfinzi (durvalumab), in combination with standard-of-care chemotherapy, demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) and progression-free survival (PFS) versus chemotherapy alone as a 1st-line treatment for patients with advanced biliary tract cancer (BTC).